ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Roche’s Evrysdi significantly improves lives of babies with SMA
August 02, 2021The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA). -
Evrysdi from ROCHE gets EC nod as home treatment for spinal muscular atrophy
March 31, 2021Roche announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to ...
Pharma Sources Insight January 2025
